Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml
Articolo
Data di Pubblicazione:
2017
Citazione:
Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml / A. Iulia, C. Nicolae, V. Stefan, R. Razvan, R. Florina, L. Andrei, S. Carmen, M. Deliu-Victor, O. DE COBELLI, B. Ioan-Stelian, C. Radu-Tudor. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 13:20(2017 Aug), pp. 1793-1800.
Abstract:
Aim: To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCA) at first systematic biopsy. Patients & methods: Ninety serum samples from patients with suspicion for PCA were included. Targeted and nontargeted metabolomic analysis was performed. Results: Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCA at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCA at biopsy. Conclusion: Metabolomic analysis can predict the outcome of the first systematic biopsy.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
biopsy; metabolomics; prediction score; prostate cancer; oncology; cancer research
Elenco autori:
A. Iulia, C. Nicolae, V. Stefan, R. Razvan, R. Florina, L. Andrei, S. Carmen, M. Deliu-Victor, O. DE COBELLI, B. Ioan-Stelian, C. Radu-Tudor
Link alla scheda completa: